|
KMID : 1038620140320030163
|
|
Radiation Oncology Journal
2014 Volume.32 No. 3 p.163 ~ p.169
|
|
|
Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma
|
|
Jung Da-Hoon
Kim Mi-Sook
Cho Chul-Koo
Yoo Hyung-Jun
Jang Won-Il
Seo Young-Seok
Paik Eun-Kyung
Kim Kum-Bae
Han Chul-Ju
Kim Sang-Bum
|
|
|
Abstract
|
|
|
Purpose: To report the results of stereotactic body radiotherapy (SBRT) for unresectable primary or recurrent cholangiocarcinoma.
Materials and Methods: From January 2005 through August 2013, 58 patients with unresectable primary (n = 28) or recurrent (n = 30) cholangiocarcinoma treated by SBRT were retrospectively analyzed. The median prescribed dose was 45 Gy in 3 fractions (range, 15 to 60 Gy in 1-5 fractions). Patients were treated by SBRT only (n = 53) or EBRT + SBRT boost (n = 5). The median tumor volume was 40 mL (range, 5 to 1,287 mL).
Results: The median follow-up duration was 10 months (range, 1 to 97 months). The 1-year, 2-year overall survival rates, and median survival were 45%, 20%, and 10 months, respectively. The median survival for primary group and recurrent group were 5 and 13 months, respectively. Local control rate at 1-year and 2-year were 85% and 72%, respectively. Disease progression-free survival rates at 1-year and 2-year were 26% and 23%, respectively. In univariate analysis, ECOG performance score (0-1 vs. 2-3), treatment volume (<50 vs. ≥50 mL), and pre-SBRT CEA level (<5 vs. ≥5 ng/mL) were significant in overall survival rate. In multivariate analysis, ECOG score (p = 0.037) and tumor volume (p = 0.030) were statistically significant. In the recurrent tumor group, patients with >12 months interval from surgery to recurrence showed statistically significant higher overall survival rate than those with ≤12 months (p = 0.026). Six patients (10%) experienced ≥grade 3 complications.
Conclusion: SBRT can be considered as an effective local modality for unresectable primary or recurrent cholangiocarcinoma.
|
|
|
KEYWORD
|
|
|
Radiosurgery, Cholangiocarcinoma
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|